Söyleyici, BegümHünkar, Pelinsu ElifGirit, ÇağrıKurt, CansuUçar, Fatih Mehmet2021-11-202021-11-2020182148-47242548-0030https://dergipark.org.tr/tr/pub/tmsj/issue/36656/420837https://dergipark.org.tr/tr/download/article-file/467625https://hdl.handle.net/20.500.14551/6060Aims: Although implantable cardioverter defibrillator reduces mortality in hypertrophic cardiomyopathy patients,inappropriate implantable cardioverter defibrillator shocks are related to increased mortality. The aim of this studyis to investigate whether a new electrocardiographic marker of T wave amplitude in lead aVR can be used to predictappropriate therapy of implantable cardioverter defibrillator (shock or anti-tachycardia pacing) in hypertrophic cardiomyopathypatients.Methods: Thirty-six hypertrophic cardiomyopathy patients, who were admitted to the outpatient clinic for pacemakercontrol, with implantable cardioverter defibrillator were retrospectively examined (mean age: 51 ± 10.2 years,72.2% male). The primary endpoint was appropriate implantable cardioverter defibrillator therapy. All hematological,biochemical and electrocardiogram parameters were measured before implantable cardioverter defibrillator wasimplanted.Results: Over a median follow-up period of 33 months, 9 (25%) patients experienced appropriate implantablecardioverter defibrillator therapy. Heart rate and QRS interval were similar between groups. QT and QTc valueswere higher in patients that received appropriate shocks. Patients who have T wave inversion were higher in therapypositive group. T wave amplitude in lead aVR values were significantly associated with appropriate therapy.Conclusion: Using simple ECG parameters, we may predict arrhythmic episodes before ICD implantation and animprovement of the medical antiarrhythmic therapy might be protective for HCM patients with ICD.eninfo:eu-repo/semantics/openAccessHypertrophiccardiomyopathydefibrillatorelectrocardiographyArticle5158420837